| Autor: |
Fleming, Ronald, Capizzi, Robert, Rosner, Gary, Oliver, Lawrence, Smith, Stephen, Schiffer, Charles, Silver, Richard, Peterson, Bruce, Weiss, Raymond, Omura, George, Mayer, Robert, Echo, David, Bloomfield, Clara, Schilsky, Richard, Fleming, R A, Capizzi, R L, Rosner, G L, Oliver, L K, Smith, S J, Schiffer, C A |
| Předmět: |
|
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Sep1995, Vol. 36 Issue 5, p425-430, 6p |
| Abstrakt: |
The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) microM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P = 0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P = 0.005) and pretreatment blast count (P = 0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P = 0.315, P = 0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink